Article
Zanubrutinib and Venetoclax for Patients With Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma With and Without Del(17p)/TP53 Mutation: SEQUOIA Arm D Results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 20 Jul 2025
Shadman Mazyar, Munir Talha, Ma Shuo, Lasica Masa, Tani Monica, Robak Tadeusz, Flinn Ian W, Brown Jennifer R, Ghia Paolo, Ferrant Emmanuelle, Tam Constantine S, Janowski Wojciech, Jurczak Wojciech, Xu Linlin, Tian Tian, Lefebure Marcus, Agresti Stephanie, Hirata Jamie, Tedeschi Alessandra
Abstract excerpt
PURPOSE: Several chronic lymphocytic leukemia (CLL) studies have demonstrated promising efficacy with the combination of BCL2 and Bruton tyrosine kinase inhibitors; however, patients with CLL with del(17p) and/or TP53 mutation (TP53mut) comprised a small percentage of study populations or were excluded entirely. The purpose of the SEQUOIA Arm D cohort was to evaluate the combination of zanubrutinib + venetoclax...
Topics
Join the communities discussing this publication.